Meropenem Agmed

Meropenem, the active ingredient in Meropenem Agmed, is a carbapenem antibiotic presented as an injectable powder for intravenous use. It treats severe Gram‑negative and Gram‑positive bacterial infections in hospitalized patients, including those with complicated intra‑abdominal, urinary tract, and respiratory infections.

GNH USA supplies Meropenem Agmed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides coverage against mixed aerobic and anaerobic pathogens. - Complicated urinary tract infections: eradicates resistant Gram‑negative organisms. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections. - Hospital‑acquired pneumonia: effective against multidrug‑resistant respiratory pathogens. - Septicemia and febrile neutropenia: offers rapid bactericidal activity in systemic infections.

Adverse reactions may occur with meropenem therapy and are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: localized skin erythema or pruritus. - Headache: transient cranial discomfort. - Elevated liver enzymes: mild transaminase increases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Anaphylaxis: acute hypersensitivity reaction requiring emergency care. - Severe allergic reactions: including Stevens‑Johnson syndrome. - Renal toxicity: acute kidney injury in susceptible individuals.

When prescribing meropenem, clinicians should consider several safety measures.

- Renal function: adjust dose in patients with impaired kidney function. - Allergy history: avoid in individuals with known carbapenem hypersensitivity. - Seizure risk: monitor patients with pre‑existing CNS disorders. - Concomitant valproic acid: anticipate reduced antiepileptic levels. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medications, requiring attention to interaction severity.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate concentrations, risking seizure breakthrough. - Warfarin: may enhance anticoagulant effect, increasing INR. - Probenecid: can alter renal clearance of meropenem.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxicity potential; monitor renal function. - Diuretics: may affect electrolyte balance; observe serum levels. - Other antibiotics: potential antagonism with bacteriostatic agents; assess therapeutic need.